ロード中...
Cancer immunotherapy‐targeted glypican‐3 or neoantigens
Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican‐3 an HLA‐24, HLA‐A2 restriction peptide with extreme cancer s...
保存先:
| 出版年: | Cancer Sci |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5834776/ https://ncbi.nlm.nih.gov/pubmed/29285841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13485 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|